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Résumé en
anglais
Triple-negative breast cancers (TNBC) represent the most aggressive form of breast
cancers and their treatment are challenging due to the tumor heterogeneity. The
high death rate and the limited systemic treatment options for TNBC necessitate the
search for alternative chemotherapeutics. We previously found that FcOHTAM, an
organometallic derivative of hydroxytamoxifen, showed in vitro a strong
antiproliferative effect on various breast cancer cell lines, including MDA-MB-231
cells, the archetype of TNBC. In this study, we developed stealth FcOHTAM loaded
lipid nanocapsules (LNCs) to further evaluate this novel drug on a TNBC
xenografted model. Cell cycle analysis of MDA-MB-231 cells confirmed the
preservation of the drug activity through LNCs causing a cycle arrest in phase S
after 48 h exposure at the IC50 concentration (2 μm). Two intraperitoneal injections
of FcOHTAM loaded LNCs (20 mg/kg) administered to luciferase-transfected MDA-
MB-231 tumors bearing mice led to a marked delay in tumor growth. As a
consequence, a significantly lower tumor volume was obtained at the end of the
experiment with a difference of 36% at day 38 compared to the untreated group.
These results represent the first evidence of an in vivo effect of FcOHTAM and
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